FDA Issues Draft Guidance on Flavored ENDS

The U.S. Food and Drug Administration has published a new draft guidance intended to clarify how flavored ENDS products should be evaluated in Premarket Tobacco Product Applications (PMTAs). The guidance, scheduled for publication in the Federal Register on March 11, outlines the agency’s current thinking on how manufacturers may demonstrate that flavored products meet the Tobacco Control Act’s “appropriate for the protection of public health” (APPH) standard.

What the Draft Guidance Says

The FDA acknowledges that flavored ENDS products vary in their appeal to youth and that some flavor categories may pose lower risks than others. Specifically, the agency identifies mint, coffee, tea, and spice as examples of flavors that may be less attractive to youth compared with fruit, candy, dessert, or other sweet profiles.

According to the guidance, manufacturers submitting PMTAs for these flavors may be able to present evidence showing:

• Lower youth interest or uptake

• Adult benefits that outweigh any residual youth risks

• Product characteristics or marketing controls that reduce youth exposure

The FDA emphasizes that these considerations are not guarantees of authorization. They are factors that may be relevant when evaluating whether a product meets the APPH standard.

Guidance Is Not a Rule

The FDA makes clear that draft guidance documents:

• Are non‑binding

• Do not establish enforceable requirements

• Do not replace statutory or regulatory standards

• Represent the agency’s current thinking, which may evolve

Manufacturers are not required to follow the guidance, and the FDA is not obligated to adhere to it when reviewing applications.

APPH Requirements Remain Unchanged

To meet the APPH standard, manufacturers must still demonstrate:

• Benefits to adult smokers, such as switching from combustible cigarettes

• Minimal risks to youth, including initiation or sustained use

• Net population‑level benefit, considering all relevant evidence

For flavored products, the FDA expects additional evidence showing that the flavor itself contributes to adult benefit beyond what tobacco or menthol flavors provide. This may include behavioral studies, clinical data, toxicological assessments, and marketing restrictions.

Potential Impact on the U.S. Vaping Market

The draft guidance may influence how manufacturers prepare PMTAs, especially for flavor categories the FDA identifies as potentially lower risk. Companies may adjust their evidence strategies, product designs, or marketing controls to align with the agency’s stated considerations.

However, several factors limit the immediate impact:

1. The guidance does not change the legal standard for authorization.
   APPH requirements remain the same.

2. The evidentiary burden remains substantial.
   Manufacturers must still provide comprehensive scientific data.

3. Authorization outcomes remain uncertain.
   The FDA will continue to evaluate applications individually.

4. Market conditions will depend on future regulatory actions.
   Binding product standards or clearer rules would have a more significant effect than guidance alone.

Looking Ahead

The draft guidance opens a 60‑day public comment period once published in the Federal Register. Stakeholders—including manufacturers, researchers, public health organizations, and consumers—will have the opportunity to provide input that may shape the final version.

Whether the guidance leads to meaningful changes in PMTA outcomes will depend on how the FDA interprets and applies these considerations in practice, and whether the agency later issues more definitive regulatory standards for flavored ENDS products.